Science that truly matters

2014 was a remarkable year for Biogen and for the patients whom we serve. We brought new therapies to market, expanded our leadership in multiple sclerosis (MS) and introduced important new treatments for hemophilia. We delivered strong financial performance through solid execution across our commercial organization. And we demonstrated that by focusing on novel science and our core areas of expertise, we can create meaningful medical advances in areas of critical unmet need — ultimately helping to improve lives, benefit healthcare systems and serve our shareholders.

Today, Biogen is more focused than ever on the areas where we can have the greatest impact through science that truly matters. In the year ahead, we hope to continue to demonstrate how the pieces we have brought together can benefit patients worldwide.

To learn more, please read our 2014 Annual Report on Form 10-K and our 2015 Proxy Statement.


As we carry forward once again as Biogen, we have a clear sense of mission and a clear focus that everything we do helps to truly make a difference in people’s lives.

— George A. Scangos, Ph.D.
Chief Executive Officer